Cassava Sciences, Inc. Made Headway

Cassava Sciences, Inc. (SAVA:NASDAQ) rocketted at $55.44, representing a gain of 141.1%. On Mon 01 Feb 21, SAVA:NASDAQ touched a New 2-Week High of $22.99. The stock got featured on our News Catalysts scanner on Tue 02 Feb 21 at 04:31 PM in the 'MISCELLANEOUS' category. From Tue 19 Jan 21, the stock recorded 66.67% Up Days and 70.00% Green Days

The stock spiked on Wed 27 Jan 21 at $23.7 with a volume of 7M+.

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.